PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE In re application of: Acton, Susan L. **Application No.: TBA** Group No.: **TBA** Filed: Herewith Examiner: **TBA** For: NOVEL PROTEIN KINASE MOLECULES AND USES THEREFOR **Mail Stop Patent Application Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450 SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE 1. [X] This submission accompanies the new application being filed concurrently herewith. This replies to the Office Letter Dated A copy of the Office Letter is enclosed. IDENTIFICATION OF PERSON MAKING STATEMENT 2. I, Tracy M. Sioussat (type or print name of person signing below) state the following: CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10* I hereby certify that, on the date shown below, this correspondence is being: MAILING × deposited with the United States Postal Service in an envelope addressed to the Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 37 C.F.R. SECTION 1.8(a) 37 C.F.R. SECTION 1.10* with sufficient postage as first class mail. × as "Express Mail Post Office to Addressee"

TRANSMISSION transmitted by facsimile to the Patent and Trademark Office. □

Date: February 25, 2004

Signature

Sean Hunziker

(type or print name of person certifying)

*WARNING:Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Mailing Label No. EV439625520US

ITEMS BEING SUBMITTED

_	~ •	• •	1	. ,
· z	Cubr	nittad	herewith	i ic/ara
J.	Suui	mucu	HOLOWIU	1 15/aic.

- A. [x] "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. Section 1.821(c) and 37 C.F.R. Sections 1.822 and 1.823.
- B. () An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. Section 1.821(d).
- C. [] A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. Sections 1.821(e) and 1.824.
- D. (x) Please transfer to this application, in accordance with 37 C.F.R. Section 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

In re application of:	Acton, Susan L.		
Application No.:	09/757,982	Group No.:	1644
Filed:	January 10, 2001	Examiner:	Haddad, Maher M.
For:	NOVEL PROTEIN KINA	SE MILECULES AND	USES THEREFOR

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form	"Sequence Identifier"
(other application)	(this application)

E.	(x)	Α	statement	that	the	content	of	each	"Sequence	Listing"	submitted	and	each	computer
		rea	adable copy	y are f	the s	ame, as	req	uired i	n 37 C.F.R.	Section 1	1.821(f).			

()	Because the statement is not made by a person registered to practice before the Offic	e,
	the Statement is verified as required in 37 C.F.R. Section 1.821(b).	

4.

5.

F. ()		ssion is made in fulfilling the requirement under 3 that the submission includes no new matter.	7 C.F.R. Section
		ement is not made by a person registered to practice verified, as required in 37 C.F.R. Section 1.821(g).	before the Office,
	AND COM	TEMENT THAT "SEQUENCE LISTING" IPUTER READABLE COPY ARE THE SAME APERS SUBMITTED INCLUDES NO NEW MAT	ΓER
4. I hereby	state:		
A. [x]		ble form submitted in this application, including those applicant's other application, is the same as the "Sequence e.	
B. (x)		lying this submission, or for which a request for transferoduce no new matter.	er from applicants'
		EXTENSION OF TERM	
5. The proc	eedings herein are for	a patent application and the provisions of 37 C.F.R. Sec	tion 1.136 apply.
(a) []		For an extension of time under 37 C.F.R. Section 1.13)) for the total number of months checked below:	6 (fees: 37 C.F.R.
Ext	ension	Fee for other than	Fee for
<u>(mc</u>	onths)	small entity	small entity
()	one month	\$ 110.00	\$ 55.00
Ö	two months	\$ 420.00	\$ 210.00
()	three months	\$ 950.00	\$ 475.00
()	four months	\$1,480.00	\$ 740.00
		Fee	\$0.00
If an addition	onal extension of time	is required, please consider this a petition therefor.	
	() An extension for \$0.00 now requested.	months has already been secured, and the fee p is deducted from the total fee due for the total months of	
		Extension fee due with this requ	est\$0.00

OR

(b) [x] Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

r	LL	PA	Y	WIEN	1

6. () Attached is a check in the	sum of \$
() Charge Account No. 5016 A duplicate of this transm	the sum of \$0.00
	FEE DEFICIENCY
8. (x) If any additional extensio	n and/or fee is required, charge Account No. 501668.
February 25, 2004	MILLENNIUM PHARMACEUTICALS, INC.
	By To M Sionsent
	Tracy M. Sioussat
	Registration No. 50,609
	40 Landsdowne Street

Cambridge, MA 02139 Telephone – (617) 374-7679 Facsimile – (617) 551-8820